Effects of buprenorphine on cardiovascular and pulmonary function in clinically normal horses and horses with chronic obstructive pulmonary disease

American Journal of Veterinary Research

Volumn 59, Issue 10, 1998, Pages 1287-1291

  Szöke, Mihàly O ^a   Blais, Diane ^a   Cuvelliez, Sophie G ^a   Lavoie, Jean Pierre ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE;

AIRWAY OBSTRUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL OXYGEN TENSION; ARTERIAL PH; ARTICLE; CARDIOVASCULAR FUNCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG EFFECT; HORSE; MEAN ARTERIAL PRESSURE; NONHUMAN; REMISSION; RESPIRATORY FUNCTION; TIDAL VOLUME;

ANALGESICS, OPIOID; ANIMALS; BLOOD GAS ANALYSIS; BLOOD PRESSURE; BUPRENORPHINE; CARDIOVASCULAR SYSTEM; FEMALE; HEART FUNCTION TESTS; HORSE DISEASES; HORSES; LUNG DISEASES, OBSTRUCTIVE; OXYGEN; RESPIRATION; RESPIRATORY FUNCTION TESTS; TIDAL VOLUME;

ANIMALIA; EQUIDAE; EQUUS CABALLUS;

EID: 0031791014     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Hall LW, Clarke KW. Veterinary anaesthesia. 9th ed. London: Baillière Tindall, 1991.
2. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Goodman X, Gilman A, Rall TW, et al, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990;485-521.
3. Plumb DC. Veterinary drugs handbook. 2nd ed. Ames, Iowa: Iowa State University Press, 1995;83-85.
4. Dum JE, Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol 1981;74:627-633.
5. Cowan A, Doxey JC, Harry EJR. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 1977;60:547-554.
6. Cowan A, Lewis JW, MacFarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977;60:537-546.
7. De Castro J, Andrieu S, Boogaerts J. Buprenorphine: a review of its pharmacological properties and therapeutical uses, in Proceedings. VI Eur Cong Anesthesiol, 1982;51-71.
8. Bullingham RES, McQuay HJ, Moore RA, et al. Buprenorphin kinetics. Clin Pharmacol Ther 1980;28:667-672.
9. Bullingham RES, McQuay HJ, Porter EJB, et al. Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. Br J Clin Pharmacol 1982;13:665-673.
10. Bullingham RES, McQuay HJ, Moore RA. Clinical pharmacokinetics of narcotic agonist-antagonist drugs. Clin Pharm 1983;8:332-343.
11. McQuay HJ, Moore RA, Bullingham RES. Buprenorphine kinetics. In: Foley KM, Inturrisi CE, eds. Advances in pain research and therapy. New York: Raven Press, 1986;271-278.
12. Waterman AE, Livingston A, Amin A. Further studies on the antinociceptive activity and respiratory effects of buprenorphine in sheep. J Vet Pharmacol Ther 1991;14:230-234.
13. Tiwari SK, Pandey SK, Bhargava MK. Clinical evaluation of certain analgesics as an adjunct to bupivacaine induced spinal anaesthesia in goat. Indian Vet J 1989;66:509-515.
14. Piercy AD. Use of buprenorphine hydrochloride. Vet Rec 1985;117:256.
15. Stock JE. Use of buprenorphine. Vet Rec 1985;117:190-191.
16. Taylor PM, Houlton JEF. Post-operative analgesia in the dog: a comparison of morphine, buprenorphine and pentazocine. J Small Anim Pract 1984;25:437-451.
17. Taylor PM, Herrtage ME. Evaluation of some drug combinations for sedation in the dog. J Small Anim Pract 1986;27:325-333.
18. Liles JH, Flecknell PA. A comparison of the effects of buprenorphine, carprofen and flunixin following laparotomy in rats. J Vet Pharmacol Ther 1994;17:284-290.
19. Flecknell PA, Liles JH, Wootton R. Reversal of fentanyl/fluanisone neuroleptanalgesia in the rabbit using mixed agonist/antagonist opioids. Lab Anim 1989;23:147-155.
20. Moore RA. Buprenorphine kinetics and metabolism - a review. In: Tobin T, Blake JW, Potter MD, et al, eds. Proceedings. 7th Intern Conf Racing Analysts Vet 1988;161-163.
21. Laviolette B, Fenwick JD, Ryan M. Gas chromatographic screening for buprenorphine and related narcotics using an electron capture detector. In: Tobin T, Blake JW, Potter MD, et al, eds. Proceedings. 7th Intern Conf Racing Analysts Vet 1988;189-196.
22. Muir WW. Standing chemical restraint in horses, tranquilizers, sedatives and analgesics. In: Muir WW, Hubbel JAE, eds. Equine anesthesia, monitoring and emergency therapy. St Louis: Mosby Year Book Inc, 1991;247-280.
23. Nolan AM, Hall LW. Combined use of sedatives and opiates in horses. Vet Rec 1984;114:63-67.
24. Thurmon JC, Benson GJ. Injectable anesthetics and anesthetic adjuncts. Vet Clin North Am Equine Pract 1987;3:15-36.
25. Jordan C. Assessment of the effects of drugs on respiration. Br J Anaesth 1982;54:763-782.
26. Beech J. Chronic obstructive lung disease. In: Smith BP, ed. Large animal internal medicine. St Louis: The CV Mosby Co, 1990;533-537.
27. Clarke AF. Chronic obstructive pulmonary disease. In: Robinson NE, ed. Current therapy in equine medicine. Philadelphia: WB Saunders Co, 1992;329-332.
28. Lavoie JP, Pascoe JR, Kurpershoek CJ. Effects of xylazine on ventilation in horses. Am J Vet Res 1992;53:916-920.
29. Lavoie JP, Phan ST, Biais D. Effects of a combination of detomidine and butorphanol on respiratory function in horses with or without chronic obstructive pulmonary disease. Am J Vet Res 1996;57:705-709.
30. Gillespie JR, Tyler WS, Eberly VE. Pulmonary ventilation and resistance in emphysematous and control horses. J Appl Physiol 1966;21:416-422.
31. Gillespie JR, Tyler WS. Chronic alveolar emphysema in the horse. In: Brandly CA, Cornelius CE, eds. Advances in veterinary science and comparative medicine. New York: Academic Press Inc, 1969;59-99.
32. Muylle E, Oyaert W. Lung function tests in obstructive pulmonary disease in horses. Equine Vet J 1973;5:37-44.
33. Willoughby RA, McDonell WN. Pulmonary function testing in horses. Vet Clin North Am Large Anim Pract 1979;1:171-196.
34. Nuytten J, Deprez P, Picavet T, et al. Comparison of different pulmonary function tests and their prognostic value in horses affected with COPD. Equine Vet Sci 1988;8:361-364.
35. Broadstone RV, Gray PR, Robinson NE, et al. Effects of xylazine on airway function in ponies with recurrent airway obstruction. Am J Vet Res 1992;53:1813-1817.
36. Robertson JT, Muir WW, Sams R. Cardiopulmonary effects of butorphanol tartrate in horses. Am J Vet Res 1981;42:41-44.
37. Muir WW, Scarda RT, Sheehan WC. Cardiopulmonary effects of narcotic agonists and a partial agonist in horses. Am J Vet Res 1978;39:1632-1635.
38. Clarke KW, Paton BS. Combined use of detomidine with opiates in the horse. Equine Vet J 1988;20:331-334.
39. Combie JD, Dougherty J, Nugent E, et al. The pharmacology of narcotic analgesic in the horse. IV. Dose and time-response relationships for behavioral response to morphine, meperidine, pentazocine, anileridine, methadone, and hydromorphine. J Equine Med Surg 1979;3:377-385.
40. Kalpravidh M, Lumb WV, Wright M, et al. Analgesic effects of butorphanol in horses: dose-response studies. Am J Vet Res 1984;45:211-216.
41. Tobin T, Woods WE. Pharmacology review: actions of central stimulant drugs in the horse. Equine Vet J 1979;3:60-66.
42. Roques BP. Pharmacologie des différentes classes de récepteurs opioïdes cérébraux (1). Rec Med Vet 1986;162:1321-1331.